Bristol Myers Squibb clears key cancer drug hurdle, shares in focus after FDA panel backing

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 07:18.

Bristol Myers Squibb (US0897961004) secured a marked regulatory milestone this week as a US Food and Drug Administration advisory committee backed expanded use of its CAR-T therapy Abecma for multiple myeloma, as reported by Reuters. The New York based biopharma group, whose shares trade on the NYSE, now awaits the FDA's final decision on the label extension for the therapy it co-developed with 2seventy bio.

FDA panel backs Abecma expansion

The FDA Oncologic Drugs Advisory Committee voted clearly in favor of broadening Abecma's use in certain multiple myeloma patients after reviewing efficacy and safety data, according to a detailed Reuters account of the meeting. The Reuters coverage of the FDA panel vote highlights that experts viewed the benefit-risk profile as positive despite known side effects such as cytokine release syndrome and neurotoxicity.

Abecma, a BCMA-directed CAR-T cell therapy originally approved for heavily pretreated multiple myeloma patients, could move earlier in the treatment sequence if the FDA follows the committee's recommendation, extending its commercial runway in a competitive field that includes Johnson & Johnson and Legend Biotech's Carvykti. The advisory vote does not guarantee approval but historically carries substantial weight in FDA decision making and therefore matters for Bristol Myers Squibb's oncology franchise.

Analysts assess revenue impact and pipeline mix

Equity analysts are already assessing what a broader Abecma label could mean for Bristol Myers Squibb's revenue mix, which has been in transition as legacy blockbusters such as Revlimid face generic erosion. A recent note from JPMorgan cited by MarketScreener points out that CAR-T therapies, including Abecma, form part of the company's strategy to rebuild growth in oncology through innovative modalities rather than traditional small molecules. The MarketScreener analyst overview shows that most covering brokers currently rate Bristol Myers Squibb stock between Hold and Buy, with a moderate upside implied by consensus price targets.

Beyond Abecma, the company's late-stage pipeline includes agents such as the TYK2 inhibitor deucravacitinib and several immuno-oncology combinations, which analysts from firms like Goldman Sachs and Morgan Stanley describe as important for offsetting declining sales of mature therapies. Bristol Myers Squibb's own pipeline overview presents a broad portfolio across oncology, cardiovascular, immunology and hematology, underlining management's emphasis on high-value specialty drugs rather than primary care products.

The product behind the stock

Abecma is a BCMA-targeting CAR-T cell therapy designed for adults with relapsed or refractory multiple myeloma who have received several prior lines of treatment. The autologous therapy uses a patient’s own T cells, modified ex vivo to recognize and attack myeloma cells, reflecting Bristol Myers Squibb's focus on complex, high-value specialty treatments.

Where the stock trades today

As of the latest available data on 2026-06-26, 05:10, Bristol Myers Squibb shares trade on the NYSE around 44.50 US dollars, according to recent price information from MarketWatch and other exchange-based quote services.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.